15 citations,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
16 citations,
June 2021 in “Journal of Dermatological Treatment” Minoxidil effectively treats hair loss, especially androgenetic alopecia, but needs more research for better understanding.
February 2024 in “Curēus” Secukinumab can cause hair loss, which may improve after stopping the medication.
59 citations,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
1 citations,
September 2020 in “Cochrane library (CD-ROM)” The analysis aims to identify the most effective and safest treatments for alopecia areata.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
January 2024 in “Dermatology practical & conceptual” Male gender and family history predict alopecia areata recurrence.
June 2023 in “Dermatology and therapy” The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.
May 2023 in “Dermatology and therapy” The document concludes that identifying the cause of eyebrow and eyelash loss is key to treating it and improving quality of life.
April 2023 in “Medizinische Genetik” New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.
The document concludes that diagnosing female hair loss requires careful examination, with treatments varying by condition and psychological support often necessary.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
20 citations,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
July 2024 in “Clinical Cosmetic and Investigational Dermatology” Exosomes can help promote hair growth and may treat hair loss.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
19 citations,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
April 2024 in “Tạp chí Y học Thảm hoạ và Bỏng” Choosing the right treatment for hair loss is complex and depends on effectiveness, side effects, practicality, and cost.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
December 2023 in “European Journal of Medicinal Chemistry” Natural products might be safe, effective, and affordable treatments for hair loss.
2 citations,
February 2021 in “The Journal of clinical and aesthetic dermatology” Understanding the cause of bitemporal hair loss is key to deciding the right treatment.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
October 2023 in “Journal of Drug Delivery Science and Technology” Electrospun nanofibers might be a promising new treatment for hair loss.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
6 citations,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
79 citations,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
41 citations,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.